Preclinical reports showed that semorinemab reduced tau-mediated neuronal toxicity and tau deposition with a safe profile [157], but in a clinical setting in a phase II trial, it failed to improve clinical symptoms in AD patients [158,159]. This evidence concerns the gene MAPT and Alzheimer disease.